O
NMRA icon

OrbiMed’s Neumora Therapeutics NMRA Stock Holding History

OrbiMed’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.64M Buy
+2,139,882
New +$4.07M 0.07% 111
2025
Q1 		– Sell
-804,996
Closed -$8.53M – 122
2024
Q4 		$8.53M Sell
804,996
-695,004
-46% -$8.33M 0.18% 73
2024
Q3 		$19.8M Hold
1,500,000
– – 0.36% 64
2024
Q2 		$14.7M Hold
1,500,000
– – 0.29% 64
2024
Q1 		$20.6M Hold
1,500,000
– – 0.38% 63
2023
Q4 		$25.6M Hold
1,500,000
– – 0.51% 56
2023
Q3 		$21.2M Buy
+1,500,000
New +$18.7M 0.45% 61

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

OrbiMed's NMRA Position: Q2 2026 in Review

OrbiMed opened a new position in Neumora Therapeutics (NMRA) in Q2 2026: 2,139,882 shares worth $3.64M. The stake represents 0.07% of the portfolio and ranks #111 among its holdings. This is a return to the name: OrbiMed previously reported a position in NMRA as recently as Q4 2024.

OrbiMed first reported a position in NMRA in Q3 2023 and has held it in 7 quarters since. The position peaked at $25.6M in Q4 2023. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • OrbiMed held 2,139,882 shares of Neumora Therapeutics worth $3.64M as of Q2 2026.
  • Neumora Therapeutics was a new OrbiMed position in Q2 2026.
  • Neumora Therapeutics made up 0.07% of OrbiMed's portfolio in Q2 2026, its #111 holding.
  • OrbiMed first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 7 quarters since.
  • OrbiMed's Neumora Therapeutics position peaked at $25.6M in Q4 2023.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.